Ovarian cancer and high-risk women - Implications for prevention, screening, and early detection

Gynecologic Oncology

Volumn 91, Issue 1, 2003, Pages 15-31

  Modugno, Francesmary ^a   Boyd, Jeff ^a   Baum, Andrew ^a,b   Bigbee, William L ^a,b   Cramer, Daniel ^a,c   Ferrell, Robert ^a,b   Gallion, Holly H ^a,b   Greene, Mark H ^a   Goldman, Patricia ^a   Johnson, Karen A ^a   Junker, Barbara ^a   Kuller, Lewis ^a,b   Kurman, Robert J ^a   Maihle, Nita ^a,d   Narod, Steven ^a   Ness, Roberta B ^a,b   Risch, Harvey ^a,e   Rodriguez, Gustavo ^a   Sadetzki, Siegal ^a   Skates, Steven ^a,c   Stein, Maxine ^a   Weissfeld, Joel L ^a,b   more..

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MAYO CLINIC   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIINFLAMMATORY AGENT; BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN; CYCLOOXYGENASE 2 INHIBITOR; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; FENRETINIDE; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; RETINOID; VITAMIN D;

CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CARCINOGENESIS; CLINICAL TRIAL; DRUG EFFECT; DRUG FORMULATION; DRUG MECHANISM; DRUG MEGADOSE; EARLY DIAGNOSIS; ENDOMETRIOSIS; ENDOMETRIUM; GENE MUTATION; GENOMICS; HIGH RISK POPULATION; HUMAN; LOW DRUG DOSE; MENSTRUAL CYCLE; MORBIDITY; NONHUMAN; ONCOGENE; OVARY CANCER; OVARY CYST; OVULATION; PARITY; PELVIC INFLAMMATORY DISEASE; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SALPINGOOOPHORECTOMY; TRANSVAGINAL ECHOGRAPHY; TREATMENT OUTCOME;

EID: 0141817892     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(03)00254-3     Document Type: Review

References (261)

1. American Cancer Society Facts and Figures, 2001.
2. Easton D.F., Ford D., Matthews F.E., Peto J. The genetic epidemiology of ovarian cancer. Sharp F., Mason P., Blackett T., Berek J. Ovarian cancer 3. vol 3:1995;Chapman & Hall Medical, London.
3. Houlston RS, Collins A, Slack J, Campbell S, Collins WP, Whitehead MI, Morton NE. Genetic epidemiology of ovarian cancer: segregation analysis. Ann Hum Genet 1991;55.
4. Narod S.A. Genetics of breast and ovarian cancer. Br Med Bull. 50:1994;656.
5. Risch H.A., McLaughlin J.R., Cole D.E., Rosen B., Bradley L., Kwan E., Jack E., Vesprini D.J., Kuperstein G., Abrahamson J.L., Fan I., Wong B., Narod S.A. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 68:2001;700-710.
6. Boyd J., Sonoda Y., Federici M.G., Bogomolniy F., Rhei E., Maresco D.L., Saigo P.E., Almadrones L.A., Barakat R.R., Brown C.L., Chi D.S., Curtin J.P., Poynor E.A., Hoskins W.J. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA. 283:2000;2260-2265.
7. Rubin S.C., Benjamin I., Behbakht K., Takahashi H., Morgan M.A., LiVolsi V.A., Berchuck A., Muto M.G., Garber J.E., Weber B.L., Lynch H.T., Boyd J. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med. 335:1996;1413-1416.
8. Ford D., Easton D.F., Bishop D.T., Narod S.A., Goldgar D.E. Risks of cancer in BRCA1-mutation carriers. Lancet. 343:1994;692-695.
9. Struewing J.P., Hartge P., Wacholder S., Baker S.M., Berlin M., McAdams M., Timmerman M.M., Brody L.C., Tucker M.A. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 336:1997;1401-1408.
10. Kauff N.D., Satagopan J.M., Robson M.E., Scheuer L., Hensley M., Hudis C.A., Ellis N.A., Boyd J., Borgen P.I., Barakat R.R., Norton L., Castiel M., Nafa K., Offit K. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 346:1923;1609-1615.
11. Rebbeck T.R., Lynch H.T., Neuhausen S.L., Narod S.A., Van't Veer L., Garber J.E., Evans G., Isaacs C., Daly M.B., Matloff E., Olopade O.I., Weber B.L. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 346:1923;1616-1622.
12. Modan B., Hartge P., Hirsh-Yechezkel G., Chetrit A., Lubin F., Beller U., Ben Baruch G., Fishman A., Menczer J., Ebbers S.M., Tucker M.A., Wacholder S., Struewing J.P., Friedman E., Piura B. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med. 345:1926;235-240.
13. Narod S.A., Sun P., Ghadirian P., Lynch H., Issacs C., Garber J., Weber B., Karlan B., Fishman D., Rosen B., Tung N., Neuhausen S.L. Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations a case-control study . Lancet. 357:2001;1467-1470.
14. Narod S.A., Risch H.A., Moslehi R., Dorum A., Neuhausen S., Olsson H., Provencher D., Radice P., Evans G., Bishop S., Brunet J.S., Ponder B.A. Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med. 339:1998;424-428.
15. Ness R.B., Grisso J., Klapper J., Schlesselman J.J., Silverzweig S., Vergona R., Morgan M., Wheeler J.E. Risk of ovarian cancer in relation to estrogen dose and use characteristics of oral contraceptives. Am J Epidemiol. 152:2000;233-241.
16. Prorok P.C., Andriole G.L., Bresalier R.S., Buys S.S., Chia D., Crawford E.D., Fogel R., Gelmann E.P., Gilbert F., Hasson M.A., Hayes R.B., Johnson C.C., Mandel J.S., Oberman A., O'Brien B., Oken M.M., Rafla S., Reding D., Rutt W., Weissfeld J.L., Yokochi L., Gohagan J.K. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials. 21:2000;273S-309S.
17. Srivastava S., Rossi S.C. Early detection research program at the NCI. Int J Cancer. 69:1996;35-37.
18. Scully R. Classification of human ovarian tumors. Environ Health Perspect. 73:1987;15-24.
19. Wu M.L., Whittmore A.S., Paffengarger R.S., Sarles D.L., Kamper J.B., Grosser S., Jung D.L., Ballon S., Hendrickson M., Mohle-Boetani J. Personal and environmental characteristics related to epithelial ovarian cancer. I. Reproductive and menstrual events and oral contraceptive use. Am J Epidemiol. 128:1988;1216-1227.
20. Tzonou A., Day N.E., Trichopoulos D., Walker A., Saliaraki M., Papapostolou M., Polychronopoulou A. The epidemiology of ovarian cancer in Greece a case-control study . Eur J Clin Oncol. 20:1984;1045-1052.
21. Newhouse M.L., Pearson R.M., Fullerton J.M., Boeson E.A., Shannon H.S. A case-control study of the ovary. Br J Prev Soc Med. 31:1977;148-153.
22. McGowan L., Parent L., Lednar W., Norris H.J. The women at risk for developing ovarian cancer. Gynecol Oncol. 7:1979;325-344.
23. Booth M., Beral V., Smith P. Risk factors for ovarian cancer a case-control study . Br J Cancer. 60:1989;592-598.
24. Hildreth N.G., Kelsey J.L., LiVolsi V.A., Fisher D.B., Holford T.R., Mostow E.D., Schwartz P.E., White C. An epidemiology study of epithelial carcinoma of the ovary. Am J Epidemiol. 114:1981;398-405.
25. Casagrande J.T., Louie E.W., Pike M.C., Roy S., Ross R.K., Henderson B.E. "Incessant ovulation" and ovarian cancer. Lancet. ii:1979;170-173.
26. Rosenberg L., Shapiro S., Slone D., Kaufman D.W., Helmrich S.P., Miettinen O.S., Stoley P.D., Rosenshein N.S., Schottenfeld D., Engle R.L. Epithelial ovarian cancer and combination oral contraceptives. JAMA. 247:1982;3210-3212.
27. Mori M., Kiyosawa H., Miyake H. Case-control study of ovarian cancer in Japan. Cancer. 53:1984;2746-2752.
28. Kvale G., Heuch I., Nilssen S., Beral V. Reproductive factors and risk of ovarian cancer a prospective study . Int J Cancer. 42:1988;246-251.
29. Joly D.J., Lilienfeld A.M., Diamond E.L., Bross I.D. An epidemiologic study of the relationship of reproductive experience to cancer of the ovary. Am J Epidemiol. 99:1974;190-209.
30. Cramer D.W., Hutchison G.B., Welch W.R., Scully R.E., Ryan K.J. Determinants of ovarian cancer risk. J Natl Cancer Inst. 71:1983;711-716.
31. Franceschi S., La Vechhia C., Helmrich S.P., Mangioni C., Tognoni G. Risk factors for epithelial ovarian cancer in Italy. Am J Epidemiol. 115:1982;714-719.
32. La Vecchia C., Decarli A., Franceschi S., Regallo M., Tognoni G. Age at first birth and the risk of epithelial ovarian cancer. J Nat Cancer Ins. 73:1984;663-666.
33. Nasca P.C., Greenwald P., Chorost S., Richart R., Caputo T. An epidemiologic case-control study of ovarian cancer and reproductive factors. Am J Epidemiol. 119:1984;705-713.
34. Risch H.A., Weiss N.S., Lyon J.L., Daling J.R., Liff J.M. Events of reproductive life and the incidence of epithelial ovarian cancer. Am J Epidemiol. 117:1983;128-139.
35. Voight L.F., Harlow B.L., Weiss N.S. The influence of age at first birth and parity on ovarian cancer risk. Am J Epidemiol. 124:1986;490-491.
36. Wydner E.L., Dodo H., Barber H.R. Epidemiology of cancer of the ovary. Cancer. 23:1969;352-370.
37. Mori M., Harabuchi I., Miyake H., Casagrande J.T., Henderson B.E., Ross R.K. Reproductive, genetic, and dietary risk factors for ovarian cancer. Am J Epidemiol. 128:1988;771-777.
38. Gwinn M.L., Lee N.C., Rhodes P.H., Layde P.M., Rubin G.L. Pregnancy, breast feeding, and oral contraceptives and the risk of epithelial ovarian cancer. J Clin Epidemiol. 43:1990;559-568.
39. Stanford J.L. Oral contraceptives and neoplasia of the ovary. Contraception. 43:1991;543-556.
40. Weiss N.S., Homonchuk T.A., Young J.L. Incidence of the histologic types of ovarian cancer The US Third National Cancer Survey, 1969-71 . Gynecol Oncol. 5:1977;161-167.
41. Weiss N.S., Lyon J.L., Liff J.M., Vollmer W.M., Daling J.R. Incidence of ovarian cancer in relation to the use of oral contraceptives. Int J Cancer. 28:1981;669.
42. Vessey M., Metcalfe A., Weels C., McPherson K., Westhoff C., Yates D. Ovarian neoplasms, functional ovarian cysts and oral contraceptives. Br J Med. 294:1987;1518-1520.
43. La Vecchia C., Decarli A., Fasoli M. Oral contraceptives and cancers of the breast and female genital tract. Interim results from a case-control study. Br J Cancer. 54:1986;311-317.
44. Harlow B.L., Weiss N.S., Roth G.J., Chu J., Daling J.R. Case-control study of borderline ovarian tumors reproductive history and exposure to exogenous female hormones . Cancer Res. 48:1988;5849-5852.
45. Hartge P., Schiffman M.H., Hoover R., McGowan L., Lesher L., Norris H.J. A case-control study of epithelial ovarian cancer. Am J Obstet Gynecol. 161:1989;10-16.
46. Cramer DW, Hutchison GB, Welch WR, Scully RE, Knapp RC. Factors affecting the association of oral contraceptives and ovarian cancer. N Engl J Med, 307: 1982.
47. Beral V., Hannaford P., Kay C. Oral contraceptive use and malignancies of the genital tract. Lancet. ii:1988;1331-1334.
48. The reduction in risk of ovarian cancer associated with oral-contraceptive use. N Engl J Med. 316:1987;650-655.
49. Epithelial ovarian cancer and combined oral contraceptives. Int J Epidemiol. 18:1987;538-545.
50. Shu W.O., Brinton L.A., Gao Y.T., Yuan J.M. Population-based case-control study in Shanghai. Cancer Res. 49:1989;3670-3674.
51. Willet W.C., Bain C., Hennekens C.H., Rosner B., Speizer F.E. Oral contraceptives and the risk of ovarian cancer. Cancer. 48:1981;1684-1687.
52. Whittemore A.S., Harris R., Itnyre J. Characteristics relating to ovarian cancer risk collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group . Am J Epidemiol. 136:1992;1184-1203.
53. Rosenblatt K.A., Thomas D.B. Lactation and the risk of epithelial ovarian cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Epidemiol. 22:1993;192-197.
54. Rosenblatt K.A., Thomas D.B. Reduced risk of ovarian cancer in women with a tubal ligation or hysterectomy. Cancer Epidemiol Biomarkers Prev. 5:1996;933-935.
55. Gabra H., Smyth J.F. Ovarian cancer - an introduction. Langdon S., Miller W., Berchuck A. Biology of female cancers. 1997;CRC Press, New York.
56. Claus E.B., Schildkraut J.M., Thompson W.D., Risch N.J. Attributable risk of breast and ovarian cancer. Cancer. 77:1996;2318-2324.
57. Whittemore A.S., Gong G., Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer results from three U.S. population-based case-control studies of ovarian cancer . Am J Hum Genet. 60:1997;496-504.
58. Struewing J.P., Abeliovich D., Peretz T., Avishai N., Kaback M., Collins F.S., Brody L.C. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet. 11:1995;198-200.
59. Roa B.B., Boyd A.A., Volcik K., Richards C.S. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet. 14:1996;185-187.
60. Oddoux C, Struewing JP, Clayton CM, Neuhausen S, B.L., Kaback M, Haas B, Norton L, Borgen P, Jhanwar S, Goldgar D, Ostrer H, and Offit K. The carrier frequency of BRCA2 6174delT mutation among Ashkenazi Jewish Individuals is approximately 1%. Nat Genet, 14: 1996.
61. Stratton J.F., Gayther S.A., Russell P., Dearden J., Gore M., Blake P., Easton D., Ponder B.A. Contributions of BRCA1 mutations to ovarian cancer. N Engl J Med. 336:1997;1125-1130.
62. Takahashi H., Behbakht K., McGovern P.E., Chiu H.C., Couch F.J., Weber B.L., Friedman L.S., King M.C., Furusato M., LiVolsi V.A. Mutation analysis of the BRCA1 gene in ovarian cancers. Cancer Res. 55:1995;2998-3002.
63. Mutsushima M., Kobayashi K., Emi M., Saito H., Saito J., Suzumuri K., Nakamura Y. Mutational analysis of the BRCA1 gene in 76 Japanese ovarian cancer patients four germline mutations, but no evidence of somatic mutation . Hum Mol Genet. 4:1995;1953-1956.
64. Levy-Lahad E., Catane R., Eisenberg S., Kaufman B., Hornreich G., Lishinsky E., Shohat M., Weber B.L., Beller U., Lahad A., Halle D. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families . Am J Hum Genet. 60:1997;1059-1067.
65. Moslehi R., Chu W., Karlan B., Fishman D., Risch H., Fields A., Smotkin D., Ben-David Y., Rosenblatt J., Russo D., Schwartz P., Tung N., Warner E., Rosen B., Friedman J., Brunet J.S., Narod S.A. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet. 66:2000;1259-1272.
66. Lu K.H., Cramer D.W., Muto M.G., Li E.Y., Niloff J., Mok S.C. A population-based study of BRCA1 and BRCA2 mutations in Jewish women with epithelial ovarian cancer. Obstet Gynecol. 93:1999;34-37.
67. Abeliovich D., Kaduri L., Lerer I., Weinberg N., Amir G., Sagi M., Zlotogora J., Heching N., Peretz T. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet. 60:1997;505-514.
68. vanDerLooij M., Szabo C., Besznyak I., Liszka G., Csokay B., Pulay T., Toth J., Devilee P., King M.C., Olah E. Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary. Int J Cancer. 86:2000;737-740.
69. Thompson D., Easton D. Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol Biomarkers Prev. 11:2002;329-336.
70. Gayther S.A., Mangion J., Russell P., Seal S., Barfoot R., Ponder B.A., Easton D. Variations of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet. 15:1997;103-105.
71. Gayther S.A., Warren W., Mazoyer S., Russell P.A., Harrington P.A., Chiano M., Seal S., Hamoudi R., VanRensburg E.J., Dunning A.M. Germline mutation of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet. 11:1995;428-433.
72. Holt J.T., Thompson M.E., Szabo C., Robinson-Benion C., Arteaga C.L., King M.C., Jensen R.A. Growth retardation and tumor inhibition by BRCA1. Nat Genet. 12:1996;298-302.
73. Zheng W., Luo F., Lu J.J., Baltayan A., Press M.F., Zhang Z.F., Pike M.C. Reduction of BRCA1 expression in sporadic ovarian cancer. Gynecol Oncol. 76:2000;294-300.
74. Chen Y., Lee W.H., Chew H.K. Emerging roles of BRCA1 in transcriptional regulation and DNA repair. J Cell Physiol. 181:1999;385-392.
75. Ben D.Y., Chetrit A., Hirsh-Yechezkel G., Friedman E., Beck B.D., Beller U., Ben Baruch G., Fishman A., Levavi H., Lubin F., Menczer J., Piura B., Struewing J.P., Modan B. Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol. 20:1915;463-466.
76. Ursin G., Henderson B.E., Haile R.W., Pike M.C., Zhou N., Diep A., Bernstein L. Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women? Cancer Res. 57:1997;3678-3681.
77. Narod S.A., Dube M.P., Klijn J., Lubinski J., Lynch H.T., Ghadirian P., Provencher D., Heimdal K., Moller P., Robson M., Offit K., Isaacs C., Weber B., Friedman E., Gershoni-Baruch R., Rennert G., Pasini B., Wagner T., Daly M., Garber J.E., Neuhausen S.L., Ainsworth P., Olsson H., Evans G., Osborne M., Couch F., Foulkes W.D., Warner E., Kim-Sing C., Olopade O., Tung N., Saal H.M., Weitzel J., Merajver S., Gauthier-Villars M., Jernstrom H., Sun P., Brunet J.S. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 94:(23):2002;1773-1779.
78. Fathalla M.F. Incessant ovulation - a factor in ovarian neoplasia. Lancet. ii:1971;163.
79. Cramer D.W., Welch W.R. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst. 71:1983;717-721.
80. Lacey J.V., Mink P.J., Lubin J.H., Sherman M.E., Troisi R., Hartge P., Schatzkin A., Schairer C. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA. 288:1917;334-341.
81. Rodriguez C., Patel A.V., Calle E.E., Jacob E.J. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of U.S. women. JAMA. 285:2000;1460-1465.
82. Hartge P., Hoover R., McGowan L., Norris H.J. Menopause and ovarian cancer. Am J Epidemiol. 127:1988;990-998.
83. Weiss N.S., Lyon J.L., Krishnamurthy S., Dietert S.E., Liff J.M., Kaling J.R. Non-contraceptive estrogen use and the occurrence of ovarian cancer. J Natl Cancer Inst. 68:1982;95-98.
84. Risch H.A. Estrogen replacement therapy and risk of epithelial ovarian cancer. Gynecol Oncol. 63:1996;254-257.
85. Purdie D.M., Bain C.J., Siskind V., Russell P., Hacker N.F., Ward B.G., Quinn M.A., Green A.C. Hormone replacement therapy and risk of epithelial ovarian cancer. Br J Cancer. 81:1999;559-563.
86. Polychronopoulou A., Tzonou A., Hsieh C.-C., Kaprinis G., Rebelakos A., Toupadaki N., Trichopoulos D. Reproductive variables, tobacco, ethanol, coffee and somatometry as risk factors for ovarian cancer. Int J Cancer. 55:1993;402-407.
87. LaVecchia C., Liberati A., Franeschi S. Noncontraceptive estrogen use and the occurrence of ovarian cancer. J Natl Cancer Inst. 69:1982;1207.
88. Kaufman D.W., Kelly J.P., Welch W.R., Rosenberg L., Stolley P.D., Warshauer M.E., Lewis J., Woodruff J., Shapiro S. Noncontraceptive estrogen use and epithelial ovarian cancer. Am J Epidemiol. 130:1989;1142-1151.
89. Cramer D.W., Hutchison G.S., Welch W.R., Scully R.E., Ryan K.J. Determinants of ovarian cancer risk. J Natl Cancer Inst. 71:1983;711-716.
90. Ness R.B., Cramer D.W., Goodman M.T., Kjaer S.K., Mallin K., Mosgaard B.J., Purdie D.M., Risch H.A., Vergona R., Wu A.H. Infertility, fertility drugs, and ovarian cancer a pooled analysis of case-control studies . Am J Epidemiol. 155:2002;217-224.
91. Brinton L.A., Melton L.J. III, Malkasian G.D. Jr, Bond A., Hoover R. Cancer risk after evaluation for infertility. Am J Epidemiol. 129:1989;712-722.
92. Rossing M.A., Daling J.R., Weiss N.S., Moore D.E., Self S.G. Ovarian tumors in a cohort of infertile women. N Engl J Med. 331:1994;771-776.
93. Whiteman D.C., Murphy M.F.G., Cook L.S., Cramer D.W., Hartge P., Marchbanks P.A., Nasca P.C., Ness R.B., Purdie D.M., Risch H.A. Multiple births and risk of epithelial ovarian cancer. J Natl Cancer Inst. 92:2000;1172-1177.
94. Siskind V., Green A., Bain C., Purdie C. Beyond ovulation oral contraceptives and epithelial ovarian cancer . Epidemiology. 11:2000;106-110.
95. Risch H.A. Hormonal etiology of epithelial ovarian cancer, with hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst. 90:1998;1774-1786.
96. Ness R.B., Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst. 91:1999;1459-1467.
97. Cramer D.W., Barbieri R.L., Fraer A.R., Harlow B.L. Determinants of early follicular phase gonadotrophin and estradiol concentrations in women of late reproductive age. Hum Reprod. 17:2002;221-227.
98. McNatty K.P., Makris A., Reinhold V.N., DeGrazia C., Osathamondh R., Ryan K.J. Metabolism of androstenedione by human ovarian tissues in vitro with particular reference to reductase and aromatase activity. Steroids. 34:1979;429-443.
99. Judd H.L., Judd G.E., Lucas W.E., Yen S.S. Endocrine function of the post-menopausal ovary concentration of androgens and estrogens in ovarian and peripheral vein blood . J Clin Endocrinol Metab. 39:1974;1020-1024.
100. Lau K.M., Mok S.C., Ho S.M. Expression of human estrogen receptor alpha and beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc Natl Acad Sci USA. 96:1999;5722-5727.
101. Godwin A.K., Testa J.R., Handel L.M., Liu Z., Vanderveer L.A., Tracey P.A., Hamilton T.C. Spontaneous transformation of rat ovarian surface epithelial cells association with cytogenetic changes and implications of repeated ovulation in the etiology of ovarian cancer . J Natl Cancer Inst. 84:1992;592-601.
102. Browning M.C., Anderson J. Effect of oral contraceptives on plasma testosterone concentration. Br Med J. 1:1977;107.
103. Murphy A., Cropp C.S., Smith B.S., Burkman T.R., Zacur H.A. Effect of low-dose oral contraceptive on gondotropins, androgens, and sex hormone binding globulin in nonhirsute women. Fertil Steril. 53:1990;35-39.
104. van der Vange N., Blankenstein M.A., Kloosterboer H.J., Haspels A.A., Thijssen J.H. Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone. Contraception. 41:1990;345-352.
105. Kuhnz W., Sostarek D., Gansau C., Louton T., Mahler M. Single and multiple administration of a new triphasic oral contraceptive to women pharmacokinetics of ethinyl estradiol and free total testosterone levels in serum . Am J Obstet Gynecol. 165:1991;596-602.
106. Helzlsouer K.J., Alberg A.J., Gordon G.B., Longcope C., Bush T.L., Hoffman S.C., Comstock G.W. Serum gonadotropins and steroid hormones and the development of ovarian cancer. JAMA. 274:1995;1926-1930.
107. Schidkraut J., Schwingl P.J., Bastos E., Evanoff A., Hughes C. Epithelial ovarian cancer risk among women with polycystic ovarian syndrome. Obstet Gynecol. 88:1996;549-554.
108. Insler V., Luenfeld B. Pathophysiology of polycystic ovarian disease new insights . Int J Cancer. 6:1991;1025-1029.
109. Abdel Gadir A., Khatim M.S., Mowafi R.S., Alnaser H.M., Muharib N.S., Shaw R.W. Implications of ultrasonically diagnosed polycystic ovaries. Correlations with basal hormonal profiles. Human Reprod. 7:1992;453-457.
110. Robinson S., Rodin D.A., Deacon A., Wheeler M.J., Clayton R.N. Which hormone tests for the diagnosis of polycystic ovary syndrome? Br J Prev Soc Med. 99:1992;232-238.
111. Mink P.J., Folsom A.R., Sellers T.A., Kushi L.H. Physical activity, waist-to-hip ratio and other risk factors for ovarian cancer a follow-up study of older women . Epidemiology. 7:1996;15-38.
112. Ballard-Barbash R. Anthropometry and breast cancer. Body size - a moving target. Cancer. 74:1994;1090-1100.
113. Barrett-Conner E., Ferrara A. Dehydroepiandrosterone, dehydroepiandrosterone sulfate, obesity, waist-hip ratio, and non insulin-dependent diabetes in post menopausal women the Rancho Bernardo Study . J Clin Endocrinol Metab. 81:1996;59-64.
114. De Pergola G., Triggiani V., Giorgino F., Cospite M.R., Garruti G., Cignarelli M., Guastamacchia E., Giorgino R. The free testosterone to dehydroepiandrosterone sulphate molar ratio as a marker of visceral fat accumulation in premenopausal obese women. Int J Obes Relat Metab Disord. 18:1994;659-664.
115. Evans D.J., Hoffman R.G., Kalkhoff R.K., Kissebah A.H. Relationship of androgenic activity to body fat topography, fat cell morphology, and metabolic aberrations in premenopausal women. J Clin Endocrinol Metab. 57:1983;304-310.
116. Kaye S.A., Folsom A.R., Soler J.T., Prineas R.J., Potter J.D. Associations of body mass and fat distribution with sex hormone concentration in post-menopausal women. Int J Epidemiol. 20:1991;151-156.
117. Kirschner M.A., Samojlik E. Sex hormone metabolism in upper and lower body obesity. Int J Obes. 15:1991;101-108.
118. Luthold W.W., Borges M.F., Marcondes J.A., Hakohyama M., Wajchenberg B.L., Kirschner M.A. Serum testosterone fractions in women; normal and abnormal clinical states. Metabolism. 42:1993;638-643.
119. Mantzoros C.S., Georgiadis E.I., Evangelopoulou K., Katsilambros N. Dehydroepiandrosterone sulfate and testosterone are independently associated with body fat distribution in premenopausal women. Epidemiology. 7:1996;513-516.
120. Williams D.P., Boyden T.W., Pamenter R.W., Lohman T.G., Going S.B. Relationship of body fat percentage and fat distribution with dehydroepiandrosterone sulfate in premenopausal females. J Clin Endocrinol Metab. 77:1993;80-85.
121. Yen S.S. Endocrinology of pregnancy. Creasy R.K., Resnik R. Maternal-fetal medicine principles and practice . 3rd ed:1994;382-412 Saunders, Philadelphia.
122. King R.J. Biology of female sex hormone action in relation to contraceptive agents and neoplasia. Contraception. 43:1991;527-542.
123. Rosenberg L., Palmer J.R., Zauber A.G., Warshauer M.E., Lewis J.L., Strom B.L., Harlap S., Shapiro S. A case-control study of oral contraceptive use and invasive epithelial ovarian cancer. Am J Epidemiol. 139:1994;654-661.
124. Zeimet A.G., Muller-Holzner E., Marth C., Daxenbichler G. Immunocytochemical versus biochemical receptor determination in normal and tumorous tissues of the female reproductive tract and the breast. JAMA. 49:1994;365-372.
125. Cook L.S., Kamb M.L., Weiss N.S. Perineal powder exposure and the risk of ovarian cancer. Am J Epidemiol. 145:1997;459-465.
126. Cramer D.W., Welch W.R., Scully R.E., Wojciechowski C.A. Ovarian cancer and talc a case-control study . Cancer. 50:1982;372-376.
127. Cramer D.W., Liberman R.F., Titus-Ernstoff L., Welch W.R., Greenberg E.R., Baron J.A., Harlow B.L. Genital talc exposure and risk of ovarian cancer. Int J Cancer. 81:1999;351-356.
128. Gertig D.M., Hunter D.J., Cramer D.W., Colditz G.A., Speizer F.E., Willett W.C., Hankinson S.E. Prospective study of talc use and ovarian cancer. J Natl Cancer Inst. 92:2000;249-252.
129. Ness R.B., Grisso J., Cottreau C., Klapper J., Vergona R., Wheeler J.E., Morgan M., Schlesselman J.J. Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology. 11:2000;111-117.
130. Whittemore A.S., Wu M.L., Pafenbarger R.S., Sarles D.L., Kampert J.B., Grosser S., Jung D.L., Ballon S., Hendrickson M. Personal and environmental characteristics related to epithelial ovarian cancer. Am J Epidemiol. 128:1988;1228-1240.
131. Wong C., Hempling R.E., Piver M.S., Natarajan N., Mettlin C.J. Perineal talc exposure and subsequent epithelial ovarian cancer a case-control study . Obstet Gynecol. 93:1999;372-376.
132. Weiss N.S., Harlow B.L. Why does hysterectomy without bilateral oophorectomy influence the subsequent incidence of ovarian cancer? Am J Epidemiol. 124:1986;856-858.
133. Irwin K.L., Weiss N.S., Lee N.C., Peterson H.B. Tubal sterilization, hysterectomy, and the subsequent occurrence of epithelial ovarian cancer. Am J Epidemiol. 134:1991;362-369.
134. Cramer D.W., Xu H. Epidemiologic evidence for uterine growth factors in the pathogenesis of ovarian cancer. Ann Epidemiol. 5:1995;310-314.
135. Hankinson S.E., Hunter D.J., Colditz G.A., Willett W.C., Stampfer M.J., Rosner B., Hennekens C.H., Speizer F.E. Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. JAMA. 270:1993;2813-2818.
136. Miracle-McMahill H.L., Calle E.E., Kosinski A.S., Rodriguez C., Wingo P.A., Thun M.J., Heath C.W. Jr. Tubal ligation and fatal ovarian cancer in a large prospective cohort study. Am J Epidemiol. 145:1997;349-357.
137. Loft A., Lidegaard O., Tabor A. Incidence of ovarian cancer after hysterectomy a nationwide controlled follow up . Br J Obstet Gynecol. 104:1997;1296-1301.
138. Kreiger N., Sloan M., Cotterchio M., Parsons P. Surgical procedures associated with risk of ovarian cancer. Int J Epidemiol. 26:1997;710-715.
139. Cornelison T.L., Natarajan N., Piver M.S., Mettlin C.J. Tubal ligation and the risk of ovarian carcinoma. Cancer Detect Prev. 21:1997;1-6.
140. Green A., Purdie D., Bain C., Siskind V., Russell P., Quinn M., Ward B. Tubal sterilisation, hysterectomy and decreased risk of ovarian cancer. Survey of Women's Health Study Group. Int J Cancer. 71:1997;948-951.
141. Rosenblatt K.A., Thomas D.B. Reduced risk of ovarian cancer in women with a tubal ligation or hysterectomy. The World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Cancer Epidemiol Biomarkers Prev. 5:1996;933-935.
142. Brinton L.A., Gridley G., Persson I., Baron J., Bergqvist A. Cancer risk after a hospital discharge diagnosis of endometriosis. Am J Obstet Gynecol. 176:1997;572-579.
143. Shu X.O., Brinton L.A., Gao Y.T., Yuan J.M. Population-based case-control study of ovarian cancer in Shanghai. Cancer Res. 49:1989;3670-3674.
144. Risch H.A., Howe G.R. Pelvic inflammatory disease and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 4:1995;447-451.
145. Cramer D.W., Harlow B.L., Titus-Ernstoff L., Bohlke K., Welch W.R., Greenberg E.R. Over-the-counter analgesics and risk of ovarian cancer. Lancet. 351:1998;104-107.
146. Tavani A., Gallus S., La Vecchia C., Conti E., Montella M., Franceschi S. Aspirin and ovarian cancer an Italian case-control study . Ann Oncol. 11:2000;1171-1173.
147. Moysich K.B., Mettlin C., Piver M.S., Natarajan N., Menezes R.J., Swede H. Regular use of analgesic drugs and ovarian cancer risk. Cancer Epidemiol Biomarkers Prev. 10:2001;903-906.
148. Akhmedkhanov A., Toniolo P., Zeleniuch-Jacquotte A., Kato I., Koenig K.L., Shore R.E. Aspirin and epithelial ovarian cancer. Prev Med. 33:2001;682-687.
149. Oral E., Arici A. Pathogenesis of endometriosis. Obstet Gynecol Clin North Am. 24:1997;219-233.
150. Rodriguez G.C., Walmer D.K., Cline M., Krigman H., Lessey B.A., Whitaker R.S., Dodge R., Hughes C.L. Effect of progestin on the ovarian epithelium of macaques cancer prevention through apoptosis? J Soc Gynecol Invest. 5:1998;271-276.
151. Brenner R., Slayden O.D. Cyclic changes in the primate oviduct and endometrium. Knobil E., Neill J.D. 1994;541-569 Raven Press, New York.
152. Hotchkiss J., Knobil E. The menstrual cycle and its neuroendocrine control. Neill J.D. 1994;711-736 Raven Press, New York.
153. Kaiserman-Abramof I.R., Padykula H.A. Ultrastructural epithelial zonation of the primate endometrium (rhesus monkey). Am J Anat. 184:1989;13-30.
154. Schildkraut J.M., Calingaert B., Marchbanks P.A., Moorman P.G., Rodriguez G.C. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst. 94:2002;32-38.
155. Rodriguez G.C., Nagarsheth N.P., Lee K.L., Bentley R.C., Walmer D.K., Cline M., Whitaker R.S., Isner P., Berchuck A., Dodge R.K., Hughes C.L. Progestin-induced apoptosis in the Macaque ovarian epithelium differential regulation of transforming growth factor-beta . J Natl Cancer Inst. 94:2002;50-60.
156. Butta A., MacLennan K., Flanders K.C., Sacks N.P., Smith I., McKinna A., Dowsett M., Wakefield L.M., Sporn M.B., Baum M. Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res. 52:1992;4261-4264.
157. Reiss M. Transforming growth factor-beta and cancer a love-hate relationship? Oncol Res. 9:1997;447-457.
158. Yancik R. Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer. 71:1993;517-523.
159. Riman T., Dickman P.W., Nilsson S., Correia N., Nordlinder H., Magnusson C.M., Weiderpass E., Persson I.R. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst. 94:2003;497-504.
160. principal results from the Women's Health Initiative randomized controlled tria. JAMA. 288:2002;321-333.
161. Rodriguez-Burford C., Barnes M.N., Oelschlager D.K., Myers R.B., Talley L.I., Partridge E.E., Grizzle W.E. Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines preclinical evaluation of NSAIDs as chemopreventive agents . Clin Cancer Res. 8:2002;202-209.
162. Ferlay Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide, Version 1.0 ed. IARC CancerBase No. 5. Lyon, IARC Press, 2001.
163. Atlas of Cancer Mortality in the US: 1950-1994. 11995. NIH Publication No. 99-4564.
164. Schwartz G.G., Hulka B.S. Is vitamin D deficiency a risk factor for prostate cancer? Anticancer Res. 10:1990;1307-1311.
165. Schwartz G.G., Oeler T.A., Uskokovic M.R., Bahnson R.R. Human prostate cancer cells inhibition of proliferation by vitamin D analogs . Anticancer Res. 14:1994;1077-1081.
166. Corder E.H., Guess H.A., Hulka B.S., Friedman G.D., Sadler M., Vollmer R.T., Lobaugh B., Drezner M.K., Vogelman J.H., Orentreich N. Vitamin D and prostate cancer a prediagnostic study with stored sera . Cancer Epidemiol Biomarkers Prev. 2:1993;467-472.
167. Fredrickson T.N. Ovarian tumors of the hen. Environ Health Perspect. 73:1987;35-51.
168. Design of the women's health initiative clinical trial and observational study group. Control Clin Trials. 19:1998;61-109.
169. DePalo G., Mariani L., Camerini T., Marubini E., Formelli F., Pasini B., Decensi A. Veronesi U Effect of fenretinide on ovarian carcinoma occurrence. Gynecol Oncol. 86:2002;24-27.
170. DePalo G., Camerini T., Marubini E., Costa A., Formelli F., Del Vecchio M., Mariani L., Miceli R., Mascotti G., Magni A., Campa T., Di Mauro M.G., Attili A., Maltoni C., Del Turco M.R., Decensi A., D'Aiuto G., Veronesi U. Chemoprevention trial of contralateral breast cancer with fenretinide. Rationale, design, methodology, organization, data management, statistics and accrual. Tumori. 83:1997;884-894.
171. Zhang D., Holmes W.F., Wu S., Soprano D.R., Soprano K.J. Retinoids and ovarian cancer. J Cell Physiol. 185:2000;1-20.
172. Formelli F., Cleris L. Synthetic retinoid fenretinide is effective against a human ovarian carcinoma xenograft and potentiates cisplatin activity. Cancer Res. 53:1993;5374-5376.
173. Supino R., Crosti M., Clerici M., Warlters A., Cleris L., Zunino F., Formelli F. Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression. Int J Cancer. 65:1996;491-497.
174. Sabichi A.L., Hendricks D.T., Bober M.A., Birrer M.J. Retinoic acid receptor beta expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide. J Natl Cancer Inst. 90:1998;597-605.
175. Guruswamy S., Lightfoot S., Gold M.A., Hassan R., Berlin K.D., Ivey R.T., Benbrook D.M. Effects of retinoids on cancerous phenotype and apoptosis in organotypic cultures of ovarian carcinoma. J Natl Cancer Inst. 93:2001;516-525.
176. Langdon S.P., Rabiasz G.J., Ritchie A.A., Reichert U., Buchan P., Miller W.R., Smyth J.F. Growth-inhibitory effects of the synthetic retinoid CD437 against ovarian carcinoma models in vitro and in vivo. Cancer Chemother Pharmacol. 42:1998;429-432.
177. Alison R.H., Morgan K.T., Haseman J.K., Boorman G.A. Morphology and classification of ovarian neoplasms in F344 rats and (C57BL/6 X C3H)F1 mice. J Natl Cancer Inst. 78:1987;1229-1243.
178. Hewitt H.B. The choice of animal tumors for experimental studies of cancer therapy. Adv Cancer Res. 27:1978;149-200.
179. Lewis D.J. Ovarian neoplasia in the Sprague-Dawley rat. Environ Health Perspect. 73:1987;77-90.
180. Pretorius R.G., Eisenkop S., Berek J.S., Hacker N.F., Ashikaga T., Knox R.M., Lagasse L.D. Utilization of a murine model to optimize volume and dwell time of intraperitoneal cisplatin. Gynecol Oncol. 34:1989;66-69.
181. Sekiya S., Endoh N., Kikuchi Y., Katoh T., Matsuura A., Iwasawa H., Takeda B., Takamizawa H. In vivo and in vitro studies of experimental ovarian adenocarcinoma in rats. Cancer Res. 39:1979;1108-1112.
182. Pour P.M. Transplacental induction of gonadal tumors in rats by a nitrosamine. Cancer Res. 46:1986;4135-4138.
183. Nishida T., Sugiyama T., Kataoka A., Ushijima K., Yakushiji M. Histologic characterization of rat ovarian carcinoma induced by intraovarian insertion of a 7,12-dimethylbenz[a]anthracene-coated suture common epithelial tumors of the ovary in rats? Cancer. 83:1998;965-970.
184. Maekawa A., Onodera H., Tanigawa H., Kanno J., Furuta K., Hayashi Y. Induction of Sertoli cell tumors in the rat ovary by N-alkyl-N-nitrosoureas. J Cancer Res Clin Oncol. 111:1986;173-176.
185. Howell J., Marchant J., Orr J. The induction of ovarian tumors in mice with 9:10-dimethyl-1:2-benzanthracene. Br J Cancer. 8:1954;635-646.
186. Montgomery C.A., Alison R.H. Nonneoplastic lesions of the ovary in Fischer 344 rats and B6C3F1 mice. Environ Health Perspect. 73:1987;53-75.
187. Scott R.G., Tocco L.M., Granger G.A., DiSaia P.J., Hamilton T.C., Santin A.D., Hiserodt J.C. Gynecology development and characterization of a clinically useful animal model of epithelial ovarian cancer in the Fischer 344 rat . Am J Obstet Gynecol. 175:1996;593-599.
188. Orsulic S., Li Y., Soslow R.A., Vitale-Cross L.A., Gutkind J.S., Varmus H.E. Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell. 1:2002;53-62.
189. Zhang L., Yang N., Garcia J.R., Mohamed A., Benencia F., Rubin S.C., Allman D., Coukos G. Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. Am J Pathol. 161:2002;2295-2309.
190. Roby K.F., Taylor C.C., Sweetwood J.P., Cheng Y., Pace J.L., Tawfik O., Persons D.L., Smith P.G., Terranova P.F. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis. 21:2000;585-591.
191. Kahn-Dawood F.S., Dawood M.Y., Tabibzadeh S. Immunohistochemical analysis of the microanatomy of primate ovary. Biol Reprod. 54:1996;734-774.
192. Hild-Petito S., Stouffer R.L., Brenner R.M. Immunocytochemical localization of estradiol and progesterone receptors in the monkey ovary throughout the menstrual cycle. Endocrinology. 123:1988;2896-2905.
193. Hendrickx A.G., Dukelow W.R. Reproductive biology. Bennett B.T., Abbee C.R., Henrickson R. Nonhuman primates in biomedical research biology and management . 1995;147-191 Academic Press, San Diego.
194. Fredrickson T.N. Ovarian tumors of the hen. Environ Health Perspect. 73:1987;35-51.
195. Rodriguez-Burford C., Barnes M.N., Berry W., Partridge E.E., Grizzle W.E. Immunohistochemical expression of molecular markers in an avian model a potential model for preclinical evaluation of agents for ovarian cancer chemoprevention . Gynecol Oncol. 81:2001;373-379.
196. Papsolomontos P., Appleby E., Mayor O. Pathologic findings in condemned chickens a survey of 1000 carcases . Vet Rec. 85:1969;459-464.
197. Barnes M.N., Berry W.D., Straughn J.M., Kirby T.O., Leath C.A., Huh W.K., Grizzle W.E., Partridge E.E. A pilot study of ovarian cancer chemoprevention using medroxyprogesterone acetate in an avian model of spontaneous ovarian carcinogenesis. Gynecol Oncol. 87:2002;57-63.
198. Jacobs I.J., Skates S.J., MacDonald N. Screening for ovarian cancer a pilot randomized controlled trial . Lancet. 353:1999;1207-1210.
199. Bourne T.H., Whitehead M.I., Campbell S., Royston P., Bhan V., Collins W.P. Ultrasound screening for familial ovarian cancer. Gynecol Oncol. 43:1991;92-97.
200. van Nagell J.R. Jr, DePriest P.D., Reedy M.B. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol. 77:2000;350-356.
201. Liede A., Karlan B.Y., Baldwin R.L., Platt L.D., Kuperstein G., Narod S.A. Cancer incidence in a population of Jewish women at risk for ovarian cancer. J Clin Oncol. 20:2002;1570-1577.
202. United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) ( www.ukctocs.org.uk ).
203. Jacobs I.J., Skates S., Davies A.P., Woolas R.P., Jeyerajah A., Weidemann P., Sibley K., Oram D.H. Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration a prospective cohort study . Br Med J. 313:1996;1355-1358.
204. Skates S.J., Pauler D.K., Jacobs I.J. Screening based on the risk of cancer calculation from bayesian hierarchical changepoint and mixture models of longitudinal markers. J Am Stat Assoc. 96:2001;429.
205. Jacobs I., Davies A.P., Bridges J., Stabile I., Fay T., Lower A., Grudzinskas J.G., Oram D. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. Br Med J. 306:1993;1030-1034.
206. Cancer Genetics Network ( http://epi.grants.cancer.gov/CGN/).
207. Young R.H., Clement P.B., Scully R.E. The ovarian. Sternberg S.S. 1989;1655-1734 Raven Press, New York.
208. Auersperg N., Wong A.S., Choi K.C., Kang S.K., Leung P.C. Ovarian surface epithelium biology, endocrinology, and pathology . Endocr Rev. 22:2001;255-288.
209. Bjersing L., Cajander S. Ovulation and the role of the ovarian surface epithelium. Experientia. 31:1975;605-608.
210. Kruk P.A., Auersperg N. Human ovarian surface epithelial cells are capable of physically restructuring extracellular matrix. Am J Obstet Gynecol. 167:1992;1437-1443.
211. Kruk P.A., Uitto V.J., Firth J.D., Dedhar S., Auersperg N. Reciprocal interactions between human ovarian surface epithelial cells and adjacent extracellular matrix. Exp Cell Res. 215:1994;97-108.
212. Kruk P.A., Auersperg N. A line of rat ovarian surface epithelium provides a continuous source of complex extracellular matrix. In Vitro Cell Dev Biol Anim. 30A:1994;217-225.
213. Murdoch W.J. Ovarian surface epithelium during ovulatory and anovulatory ovine estrous cycles. Anat Rec. 240:1994;322-326.
214. Radisavljevic S. The pathogenesis of ovarian inclusion cysts and cystomas. Obstet Gynecol. 49:1976;424-429.
215. Jacobs I., Bast R.C. Jr. The CA 125 tumour-associated antigen a review of the literature . Hum Reprod. 4:1989;1-12.
216. Scully R.E. Pathology of ovarian cancer precursors. J Cell Biochem. 23:1995;208-218.
217. Deligdisch L., Einstein A.J., Guera D., Gil J. Ovarian dysplasia in epithelial inclusion cysts. A morphometric approach using neural networks. Cancer. 76:1995;1027-1034.
218. Dubeau L. The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma does the emperor have no clothes? Gynecol Oncol. 72:1999;437-442.
219. Wenham R.M., Lancaster J.M., Berchuck A. Molecular aspects of ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 16:2002;483-497.
220. Liu Y., Ganesan T.S. Tumour suppressor genes in sporadic epithelial ovarian cancer. Reproduction. 123:2002;341-353.
221. Berchuck A., Kohler M.F., Marks J.R., Wiseman R., Boyd J., Bast R.C. Jr. The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am J Obstet Gynecol. 170:1994;t-52.
222. Hartmann L.C., Podratz K.C., Keeney G.L., Kamel N.A., Edmonson J.H., Grill J.P., Su J.Q., Katzmann J.A., Roche P.C. Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol. 12:1994;64-69.
223. Casey G., Lopez M.E., Ramos J.C., Plummer S.J., Arboleda M.J., Shaughnessy M., Karlan B., Slamon D.J. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene. 13:1996;1971-1981.
224. Obata K., Morland S.J., Watson R.H., Hitchcock A., Chenevix-Trench G., Thomas E.J., Campbell I.G. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res. 58:1998;2095-2097.
225. Havrilesky L.J., Alvarez A.A., Whitaker R.S., Marks J.R., Berchuck A. Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations. Gynecol Oncol. 83:2001;491-500.
226. Liggett W.H., Sidransky D. Role of the p16 tumor suppressor gene in cancer. J Clin Oncol. 16:1998;1197-1206.
227. Tashiro H., Miyazaki K., Okamura H., Iwai A., Fukumoto M. c-myc over-expression in human primary ovarian tumours its relevance to tumour progression . Int J Cancer. 50:1992;828-833.
228. Wang Z.R., Liu W., Smith S.T., Parrish R.S., Young S.R. c-myc and chromosome 8 centromere studies of ovarian cancer by interphase FISH. Exp Mol Pathol. 66:1999;140-148.
229. Baker V.V., Borst M.P., Dixon D., Hatch K.D., Shingleton H.M., Miller D. c-myc amplification in ovarian cancer. Gynecol Oncol. 38:1990;340-342.
230. Teneriello M.G., Ebina M., Linnoila R.I., Henry M., Nash J.D., Park R.C., Birrer M.J. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res. 53:1993;3103-3108.
231. Suzuki M., Saito S., Saga Y., Ohwada M., Sato I. Mutation of K-RAS protooncogene and loss of heterozygosity on 6q27 in serous and mucinous ovarian carcinomas. Cancer Genet Cytogenet. 118:2000;132-135.
232. Morita K., Ono Y., Fukui H., Tomita S., Ueda Y., Terano A., Fujimori T. Incidence of P53 and K-ras alterations in ovarian mucinous and serous tumors. Pathol Int. 50:2000;219-223.
233. Dokianakis D.N., Varras M.N., Papaefthimiou M., Apostolopoulou J., Simiakaki H., Diakomanolis E., Spandidos D.A. Ras gene activation in malignant cells of human ovarian carcinoma peritoneal fluids. Clin Exp Metastasis. 17:1999;293-297.
234. Cuatrecasas M., Villanueva A., Matias-Guiu X., Prat J. K-ras mutations in mucinous ovarian tumors a clinicopathologic and molecular study of 95 cases . Cancer. 79:1997;1581-1586.
235. Caduff R.F., Svoboda-Newman S.M., Ferguson A.W., Johnston C.M., Frank T.S. Comparison of mutations of Ki-RAS and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors. Am J Surg Pathol. 23:1999;323-328.
236. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., Levin W.J., Stuart S.G., Udove J., Ullrich A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 244:1989;707-712.
237. Cheng J.Q., Godwin A.K., Bellacosa A., Taguchi T., Franke T.F., Hamilton T.C., Tsichlis P.N., Testa J.R. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA. 89:1992;9267-9271.
238. Yuan Z.Q., Sun M., Feldman R.I., Wang G., Ma X., Jiang C., Coppola D., Nicosia S.V., Cheng J.Q. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene. 19:2000;2324-2330.
239. Sun M., Wang G., Paciga J.E., Feldman R.I., Yuan Z.Q., MA X.L., Shelley S.A., Jove R., Tsichlis P.N., Nicosia S.V., Cheng J.Q. AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol. 159:2001;431-437.
240. Shayesteh L., Lu Y., Kuo W.L., Baldocchi R., Godfrey T., Collins C., Pinkel D., Powell B., Mills G.B., Gray J.W. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet. 21:1999;99-102.
241. Bellacosa A., de Feo D., Godwin A.K., Bell D.W., Cheng J.Q., Altomare D.A., Wan M., Dubeau L., Scambia G., Masciullo V. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer. 64:1995;280-285.
242. Feeley K.M., Wells M. Precursor lesions of ovarian epithelial malignancy. Histopathology. 38:2001;87-95.
243. Aunoble B., Sanches R., Didier E., Bignon Y.J. Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer (review). Int J Oncol. 16:2000;567-576.
244. Early Detection Research Network (EDRN) ( http://www3.cancer.gov/prevention/cbrg/edrn/ ).
245. Hough C.D., Sherman-Baust C.A., Pizer E.S., Montz F.J., Im D.D., Rosenshein N.B., Cho K.R., Riggins G.J., Morin P.J. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res. 60:2000;6281-6287.
246. Petricoin E.F., Ardekani A.M., Hitt B.A., Levine P.J., Fusaro V.A., Steinberg S.M., Mills G.B., Simone C., Fishman D.A., Kohn E.C., Liotta L.A. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 359:2002;572-577.
247. Cohen L.S., Escobar P.F., Scharm C., Glimco B., Fishman D.A. Three-dimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction. Gynecol Oncol. 82:2001;40-48.
248. Clinical Proteomics Program Databank (http://clinicalproteomics.steem.com).
249. Burke W., Daly M., Garber J., Botkin J., Kahn M.J., Lynch P., McTiernan A., Offit K., Perlman J., Petersen G., Thomson E., Varricchio C. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA. 277:1997;997-1003.
250. Paley P.J., Swisher E.M., Garcia R.L. Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy. Gynecol Oncol. 80:2001;176-180.
251. Aziz S., Kuperstein G., Rosen B. A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol Oncol. 80:2001;341-345.
252. Piver M.S., Jishi M.F., Tsukada Y., Nava G. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. Cancer. 71:1993;2751-2755.
253. Colditz G.A., Willett W.C., Stampfer M.J., Rosner B., Speizer F.E., Hennekens C.H. Menopause and the risk of coronary heart disease in women. New Engl J Med. 316:1987;1105-1110.
254. Suda Y., Ohta H., Makita K., Takamatsu K., Horiguchi F., Nozawa S. Influence of bilateral oophorectomy upon lipid metabolism. Maturitas. 29:1998;147-154.
255. Prior J.C., Vigna Y.M., Wark J.D., Eyre D.R., Lentle B.C., Li D.K., Ebeling P.R., Atley L. Premenopausal ovariectomy-related bone loss a randomized, double-blind, one-year trial of conjugated estrogen or medroxyprogesterone acetate . J Bone Miner Res. 12:1997;1851-1863.
256. Taylor M. Psychological consequences of surgical menopause. J Reprod Med 2001; 46: Suppl 24.
257. Shifren J.L., Nahum R., Mazer N.A. Incidence of sexual dysfunction in surgically menopausal women. Menopause. 5:1998;189-190.
258. Nathorst-Boos J., von Schoultz B., Carlstrom K. Elective ovarian removal and estrogen replacement therapy - effects on sexual life, psychological well-being and androgen status. J Psychosom Obstet Gynecol. 14:1993;283-293.
259. Nathorst-Boos J., von Schoultz B. Psychological reactions and sexual life after hysterectomy with and without oophorectomy. Gynecol Obstet Invest. 34:1992;97-101.
260. Khastgir G., Studd J. Hysterectomy, ovarian failure, and depression. Menopause. 5:1998;113-122.
261. Guzick D.S., Hoeger K. Sex, hormones, and hysterectomies. N Engl J Med. 343:2000;730-731.